Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls

NCT04701658 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04701658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04701658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2021
Completion date
June 22, 2021
Enrollment
109 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19